LON:VAL ValiRx (VAL) Share Price, News & Analysis GBX 0.56 -0.04 (-6.67%) As of 07/3/2025 11:44 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About ValiRx Stock (LON:VAL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ValiRx alerts:Sign Up Key Stats Today's Range 0.56▼ 0.6550-Day Range 0.46▼ 0.7552-Week Range 0.38▼ 3.09Volume739,426 shsAverage Volume6.15 million shsMarket Capitalization£2.13 millionP/E RatioN/ADividend Yield0.63%Price TargetN/AConsensus RatingN/A Company Overview ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development. Read More Receive VAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ValiRx and its competitors with MarketBeat's FREE daily newsletter. Email Address VAL Stock News HeadlinesValiRx signs licence with Ambrose worth GBP16 million plus royaltiesJune 20, 2025 | lse.co.ukValiRx subsidiary enters evaluation agreement with Omios BiologicsJune 3, 2025 | lse.co.ukThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 4 at 2:00 AM | Brownstone Research (Ad)ValiRx Expands Cancer Therapeutics Through Strategic PartnershipsApril 30, 2025 | tipranks.comValiRx shares fall as ends collaboration with Imperial College LondonFebruary 25, 2025 | lse.co.ukValiRx PLC Reports Change in Major Shareholder HoldingsJanuary 2, 2025 | tipranks.comValiRx plc Announces Change in Major ShareholdingsDecember 31, 2024 | tipranks.comAIM WINNERS & LOSERS: Strong 2024 for Quadrise and RosebankDecember 31, 2024 | lse.co.ukSee More Headlines VAL Stock Analysis - Frequently Asked Questions How have VAL shares performed this year? ValiRx's stock was trading at GBX 0.65 on January 1st, 2025. Since then, VAL shares have decreased by 13.8% and is now trading at GBX 0.56. How were ValiRx's earnings last quarter? ValiRx plc (LON:VAL) posted its quarterly earnings results on Friday, June, 6th. The company reported ($1.45) earnings per share (EPS) for the quarter. ValiRx had a negative trailing twelve-month return on equity of 55.84% and a negative net margin of 20,554.01%. How do I buy shares of ValiRx? Shares of VAL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of ValiRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that ValiRx investors own include Petrofac (PFC), boohoo group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Lloyds Banking Group (LLOY), IQE (IQE) and Scirocco Energy Plc (SOLO.L) (SOLO). Company Calendar Last Earnings6/06/2025Today7/04/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryPetroleum And Natural Gas Current SymbolLON:VAL CIKN/A Webwww.valirx.com Phone+44-20-30084416FaxN/AEmployees5,450Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£5.71 million Net Margins-20,554.01% Pretax MarginN/A Return on Equity-55.84% Return on Assets-35.98% Debt Debt-to-Equity Ratio0.44 Current Ratio6.65 Quick Ratio1.27 Sales & Book Value Annual Sales£27.78 thousand Price / Sales76.53 Cash FlowGBX 0.01 per share Price / Cash Flow62.50 Book ValueGBX 2.67 per share Price / Book0.21Miscellaneous Outstanding Shares379,605,148Free FloatN/AMarket Cap£2.13 million OptionableNot Optionable Beta0.59 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (LON:VAL) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ValiRx plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ValiRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
